You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 78 T-Cell, MHC i, and tumor intrinsic gene signatures predict clinical benefit and resistance to tislelizumab monotherapy in pretreated PD-L1+ urothelial carcinoma

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Biomarkers, immune monitoring, and novel technologies
78 T-Cell, MHC i, and tumor intrinsic gene signatures predict clinical benefit and resistance to tislelizumab monotherapy in pretreated PD-L1+ urothelial carcinoma

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020136019
Dec 20202405
Jan 20213603
Feb 20211404
Mar 20213006
Apr 20214608
May 20211408
Jun 2021005
Jul 20210018
Aug 2021003
Sep 20210010
Oct 202122016
Nov 202126019
Dec 20211801
Jan 20222202
Feb 20222002
Mar 202210200
Apr 20227601
May 20224403
Jun 20226000
Jul 20225402
Aug 20221400
Sep 20222403
Oct 2022601
Nov 20221601
Dec 20221602
Jan 20231202
Feb 20231802
Mar 20232002
Apr 2023400
May 20231000
Jun 2023601
Jul 20231202
Aug 2023601
Sep 20231000
Oct 2023602
Nov 20231803
Dec 20232601
Jan 20242800
Feb 20244800
Mar 20241402
Apr 20241201
May 20243601
Jun 20242000
Jul 20241201
Aug 2024801
Sep 20241601
Oct 20241203
Nov 20241803
Dec 20242803
Jan 20251204
Feb 2025003
Mar 2025001
Apr 2025005
May 2025002
Jun 2025004
Total12320193